<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00375999</url>
  </required_header>
  <id_info>
    <org_study_id>2004-232</org_study_id>
    <nct_id>NCT00375999</nct_id>
  </id_info>
  <brief_title>Docetaxel and Epirubicin in Advanced Gastric Cancer</brief_title>
  <official_title>A Phase II Study of Docetaxel and Epirubicin Combination in Patients With Advanced Gastric Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <brief_summary>
    <textblock>
      1.Study rationale:There is no standard regimen for the advanced and/or metastatic gastric
      cancer patients who relapsed after adjuvant chemotherapy or failed to first systemic
      chemotherapy. 2.Primary Objectives:To evaluate overall response rate according to the
      Response Evaluation Criteria in Solid Tumors criteria and To investigate time to response
      3.Design:single-center, Open label, Phase II study. docetaxel 75mg/m2 administered on day 1
      as intravenously combined with intravenous Epirubicin 60mg/m2 given day 2 every 3 weeks.
      4.Primary endpoints:

        1. Efficacy:overall response rate according to the Response Evaluation Criteria in Solid
           Tumors criteria, time to response, duration of response, and time to treatment failure.

        2. Safety-Adverse events and laboratory tests, graded according to the NCI Common Toxicity
           Criteria for Adverse Effects (version 3.0).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Stomach Neoplasms</condition>
  <arm_group>
    <arm_group_label>docetaxel and epirubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>salvage docetaxel and epirubicin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel and epirubicin</intervention_name>
    <arm_group_label>docetaxel and epirubicin</arm_group_label>
    <other_name>taxotere</other_name>
    <other_name>pharmorubicin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female outpatients ≥ 18 years,

          -  Eastern Cooperative Oncology Group performance status below 1, with histologically
             confirmed as gastric adenocarcinoma with inoperable and/or metastatic disease.

          -  Patients must have at least one target lesion with a minimum lesion size as per the
             Response Evaluation Criteria in Solid Tumors criteria (at least 1 unidimensional
             measurable lesion ≥ 20 mm in diameter by conventional CT or MRI scan, or ≥ 10 mm in
             diameter by spiral CT scan).

          -  Creatinine clearance ≥ 60ml/min (estimated creatinine clearance must be calculated at
             baseline for all patients.)

          -  Adequate major organ function : - Hematopoietic function: white blood cell &gt;4,000/mm3
             or absolute neutrophil count &gt; 2,000/mm3, Platelet count ≥ 100,000/mm3,- Hepatic
             function: Bilirubin &lt; 1.5 X upper normal limit, aspartate aminotransferase/alanine
             aminotransferase levels &lt;2.5 X upper normal limit, alkaline phosphatase &lt; 5 x upper
             normal limit (except in case of bone metastasis without any liver disease) - Renal
             function: Creatinine &lt;1 x upper normal limit or creatinine clearance ≥ 60ml/min.

        Exclusion Criteria:

          -  Patients must not have previously received systemic treatment (cytotoxic chemotherapy
             or active/passive immunotherapy) for advanced or metastatic disease.

          -  Adjuvant or neo-adjuvant treatment for non-metastatic (M0) disease is allowed if
             completed at least 6 months prior to initiation of study treatment.

          -  The following laboratory values: - neutrophils ≤1.5 X 109 /L, platelet count&lt;100 X 109
             /L- serum bilirubin ≥ 1.5 X upper normal limit, aspartate aminotransferase

             , alanine aminotransferase &gt; 2.5 X upper normal limit or &gt; 5 X upper normal limit in
             the case of liver metastases- Alkaline phosphatase &gt; 2.5 X upper normal limit or 5 X
             upper normal limit in the case of liver metastases or &gt; 10 X upper normal limit in the
             case of bone disease.

          -  Prior therapy with Taxotere or Epirubicin is excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Yong Cho</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yongdong Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Lim JY, Cho JY, Paik YH, Lee DK, Lee SI, Park HJ, Lee SJ, Lee KS, Yoon DS, Choi SH. Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer. Oncology. 2007;73(1-2):2-8. doi: 10.1159/000120027. Epub 2008 Mar 10.</citation>
    <PMID>18332648</PMID>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2006</study_first_submitted>
  <study_first_submitted_qc>September 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2006</study_first_posted>
  <results_first_submitted>January 14, 2014</results_first_submitted>
  <results_first_submitted_qc>January 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 3, 2014</results_first_posted>
  <last_update_submitted>January 14, 2014</last_update_submitted>
  <last_update_submitted_qc>January 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Jae Yong Cho</investigator_full_name>
    <investigator_title>Chisf of Medical oncology, Gangnam Severance Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group</title>
          <description>Salvage Chemotherapy with Docetaxel and Epirubicin for Advanced/Metastatic Gastric Cancer</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group</title>
          <description>Salvage Chemotherapy with Docetaxel and Epirubicin for Advanced/Metastatic Gastric Cancer</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="34" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Salvage Chemotherapy with Docetaxel and Epirubicin for Advanced/Metastatic Gastric Cancer</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <units>month</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" lower_limit="7.0" upper_limit="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group</title>
          <description>Salvage Chemotherapy with Docetaxel and Epirubicin for Advanced/Metastatic Gastric Cancer</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jae Yong Cho</name_or_title>
      <organization>Gangnam Severance Hospital, Yonsei University College of Medicine</organization>
      <phone>82-2-2019-4363</phone>
      <email>chojy@yuhs.ac</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

